Intracanalicular Dexamethasone Insert for Post-Corneal Cross-Linking Inflammation and Pain- The LINK Study
NCT04168112
Completed
There is no standard of care medication regimen for the management of pain and inflammation post-corneal crosslinking (CXL), although most cornea specialists agree on use of an antibiotic and steroid eye drop in the immediate postoperative period. However, steroid tapering schedule and use of additional topical non-steroidal anti-inflammatory (NSAID) eyedrops vary amongst practitioners. The goal of this study is to compare postoperative pain scores between patients receiving a tapering dose of t... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/25/2024
Locations: SightMD, Babylon, New York
Conditions: Keratoconus, Unstable, Collagen Crosslinking, Postoperative Pain
Register for Updates
Bendamustine + Pomalidomide + Dex in R/R Multiple Myeloma
NCT01754402
Active Not Recruiting
This study is designed as a phase I-II, open label, dose finding study. Study treatment will be as follows, in 28 day cycles: * Pomalidomide: once daily orally (PO) dosing on days 1-21, every 28 days * Bendamustine: once intravenously (IV) dosing on day 1, every 28 days * Dexamethasone: weekly PO or IV dosing on days 1, 8, 15, and 22. After completing 6 cycles of treatment, dexamethasone may be decreased to 20mg per investigator discretion. After completing 12 cycles of treatment, patients wi... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/25/2024
Locations: Duke University Medical Center, Durham, North Carolina
Conditions: Multiple Myeloma
Register for Updates
Distal Radius Steroid
NCT05655130
Terminated
The primary goal of this study is to compare functional outcomes (range of motion \[flexion, extension, supination, pronation\], return to work, of patients with distal radius fractures who receive intraoperative glucocorticoids to those that do not. Secondary goals include comparison of pain control (number of pain pills consumed, visual analog scale (VAS) pain scores) between patients with distal radius fractures who receive intraoperative glucocorticoids to those that do not. The primary endp... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/19/2024
Locations: Indiana Hand to Shoulder Center, Indianapolis, Indiana
Conditions: Fractures, Bone, Fractures, Closed, Radius Fracture Distal
Register for Updates
Chemotherapy With or Without Radiation, Low and Intermediate Risk Hodgkins Lymphoma, TXCH-HD-12A
NCT01858922
Completed
Subjects have a type of cancer called Hodgkin Disease (HD), a cancer of the lymph system. The lymph system is made up of tissue throughout the body that makes and stores infection-fighting cells. HD is one of the most treatable childhood cancers. The standard treatment for HD involves chemotherapy (treatment with anti-cancer drugs) and radiation therapy (the use of high-dose x-rays to get rid of cancer cells). Although they are cured from their cancer, some patients experience negative side effe... Read More
Gender:
ALL
Ages:
All
Trial Updated:
01/10/2024
Locations: Texas Children's Hospital, Houston, Texas
Conditions: Hodgkin Disease
Register for Updates
Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia
NCT00630565
Terminated
RATIONALE: Giving chemotherapy and colony-stimulating factors, such as G-CSF, may increase the number of stem cells in the blood. The stem cells are collected from the patient's blood and stored. Chemotherapy or radiation therapy is given to prepare the bone marrow for the stem cell transplant. The stem cells are then returned to the patient to replace the blood-forming cells that were destroyed by the chemotherapy and radiation therapy. PURPOSE: This clinical trial is studying how well an auto... Read More
Gender:
ALL
Ages:
70 years and below
Trial Updated:
01/09/2024
Locations: Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota
Conditions: Leukemia
Register for Updates
Intratumor Injection of Anti-Mesothelin Immunotoxin LMB-100 With Ipilimumab in Malignant Mesothelioma
NCT04840615
Terminated
Background: Mesothelioma is a type of cancer. It originates in cells that line human body cavities. Most people have advanced disease when they are diagnosed. Researchers want to see if a combination of drugs can help. Objective: To find a safe dose of LMB-100 in combination with ipilimumab when LMB-100 is injected into tumors. Eligibility: Adults ages 18 and older with malignant pleural or peritoneal mesothelioma, that cannot be cured with surgery and has not responded to standard first-li... Read More
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
01/09/2024
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Mesothelioma
Register for Updates
Prospective Study on DEXTENZA® Safety And Efficacy Following Concomitant MIGS and Cataract Surgery
NCT04200651
Terminated
In this study, the investigators are comparing dexamethasone ophthalmic insert (DEXTENZA®) to the current standard of care, prednisolone acetate 1% eye drops, in a glaucoma population receiving both cataract and minimally-invasive glaucoma surgery (MIGS). DEXTENZA® and prednisolone acetate 1% drops are both steroids used to control inflammation after eye surgery. DEXTENZA®'s method of delivery differs by offering a sustained release of steroid that does not necessitate postoperative anti-inflamm... Read More
Gender:
ALL
Ages:
21 years and above
Trial Updated:
01/07/2024
Locations: The New York Eye Surgery Center, Bronx, New York
Conditions: Glaucoma, Cataract
Register for Updates
A Rollover Study of CC-122
NCT05688475
Active Not Recruiting
The purpose of the study is to provide CC-122 treatment to participants who have been receiving treatment in other CC-122 clinical trials investigating CC-122 for more than 5 years (CC-122-ST-001 \[NCT01421524\], CC-122-ST-002 \[NCT02509039\], CC-122-DBCL-001 \[NCT02031419\], and CC-122-NHL-001 \[NCT02417285\]), receiving clinical benefit from the treatment and to monitor the safety and tolerability of CC-122.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/05/2024
Locations: Local Institution - 100, New York, New York +6 locations
Conditions: Non-Hodgkin Lymphoma
Register for Updates
Pembrolizumab, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma
NCT03506360
Completed
This phase II trial studies how well pembrolizumab works when given together with ixazomib citrate and dexamethasone in treating patients with multiple myeloma that has come back (relapsed). Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Ixazomib citrate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/04/2024
Locations: Mayo Clinic in Rochester, Rochester, Minnesota
Conditions: Recurrent Plasma Cell Myeloma
Register for Updates
Post-lesion Administration of Dexamethasone to Prevent the Development of Neuritis After Radiofrequency Ablation
NCT03247413
Terminated
Chronic neck and back pain has become one of the leading causes of disability and loss of productivity. For many patients with facet or sacroiliac joint mediated pain who have responded to diagnostic nerve blocks, radiofrequency ablation of the nerves innervating the joints can provide long term relief. Radiofrequency ablation (RFA) is a relatively safe procedure with minimal risk of adverse events. However, with any procedure involving damage to the peripheral nervous system, there is risk of p... Read More
Gender:
ALL
Ages:
Between 18 years and 90 years
Trial Updated:
01/01/2024
Locations: Johns Hopkins Hospital, Baltimore, Maryland
Conditions: Neuritis, Radiofrequency Ablation
Register for Updates
Gossypol Acetic Acid With Lenalidomide and Dexamethasone in Treating Patients With Relapsed Symptomatic Multiple Myeloma
NCT02697344
Completed
This phase I trial studies the side effects and best dose of R-(-)-gossypol acetic acid when given together with lenalidomide and dexamethasone and to see how well it works in treating patients with multiple myeloma, also known as plasma cell myeloma, that has come back after a period of improvement or has gotten worse after treatment. R-(-)-gossypol acetic acid may stop the growth of cancer cells by recognizing certain proteins and stimulating programmed cell death. Lenalidomide may stimulate o... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/26/2023
Locations: Mayo Clinic in Florida, Jacksonville, Florida
Conditions: Recurrent Plasma Cell Myeloma
Register for Updates
Alemtuzumab or Tocilizumab in Combination With Etoposide and Dexamethasone for the Treatment of Adult Patients With Hemophagocytic Lymphohistiocytosis
NCT02385110
Completed
The goal of this clinical research study is to compare the effect of adding either alemtuzumab or tocilizumab to the drug combination of etoposide and dexamethasone in controlling HLH. The safety of the drug combinations will also be studied. This is an investigational study. Alemtuzumab, etoposide, tocilizumab, and dexamethasone are not FDA approved for the treatment of HLH. Etoposide is FDA approved and commercially available for the treatment of testicular cancer and lung cancer. Alemtuzumab... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/22/2023
Locations: University of Texas MD Anderson Cancer Center, Houston, Texas
Conditions: Leukemia
Register for Updates